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ABSTRACT 
Prevalence and Severity of Smoking among 
Patients with Schizophrenia and Bipolar Disorder 
and the Effectiveness of Nicotine Replacement 
Therapy – An Observational Study 
 
INTRODUCTION 
People with mental illness are twice as likely to smoke, so there is a need to 
establish clarity regarding association of smoking and mental illness. Further, 
studies on effectiveness of nicotine replacement therapy yielded conflicting 
results. Hence, we studied the prevalence and severity of nicotine dependence 
suffering from schizophrenia and bipolar disorder and offered nicotine 
replacements to study it’s effectiveness in the follow up. 
 
AIM 
 
1) To assess prevalence and severity of nicotine dependence in patients 
suffering with schizophrenia and bipolar disorder 
 
2) To study the effectiveness of nicotine replacements 
 
METHODOLOGY 
 
     We recruited consecutive inpatients with schizophrenia or bipolar disorder 
and measured severity of illness using BPRS/YMRS/HDRS as suitable at 
baseline, 4
th
 and 12
th
 week. Fagerstrom test for nicotine dependence was used 
  
to assess severity of smoking at baseline, 4
th
 and 12
th
 week.  Nicotine 
replacements were given to those who were willing. 
 
RESULTS 
 
     The percentage of smokers among patients with schizophrenia and bipolar 
disorder were 44.2 % (n=19) and 34.0% (n=16) respectively. The severity of 
nicotine dependence fell in the mild to moderate category. At 4
th
 week, 17.6 % 
of those who were diagnosed with schizophrenia and 58.3 % of those with 
bipolar disorder were abstinent. While at the 12
th
 week, 26.7 % of 
schizophrenia and 63.7 % of bipolar disorder patients were 
abstinent(X²(1)=3.534,p=0.059).  53.8% of those who continued nicotine 
replacement therapy at 4
th
 week were abstinent [X²(1)=3.589,p=0.058] and 
88.9% at 12
th
 week [X²(1)=10.77,p=0.01]. The number of smokes showed a 
statistical significant reduction at 4
th
 and 12
th
 week when compared to baseline 
(Z=-3.519,p=0.00;Z=-2.498,p=0.013). 
 
CONCLUSION 
 
    The prevalence of smoking among male schizophrenia and bipolar affective 
disorder patients is higher than that of the general population. Greater number 
of patients with bipolar affective disorder had remained abstinent from 
smoking at 4
th
 and 12
th
 week. More number of patients who continued 
nicotine gum at 4
th
 and 12
th
 weeks remained abstinent from smoking.  
 
Keywords 
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INTRODUCTION 
 
The global burden of tobacco use in its myriad forms is enormous, given that it 
adversely affects the physical, mental and social aspects of living. It is estimated 
that nearly 450 million deaths shall be reported in the next 50 years as a result 
of cigarette smoking1 . It was further suggested in the same study that 20 to 30 
million premature deaths can be avoided in the first quarter of the century and 
150 million in the second quarter by reducing 50 % of the current smoking 
trends. Tobacco, consumed by means of smoking, remains the leading cause of 
avoidable morbidity and pre-mature mortality across the world2.  
 
  While the prevalence of smoking appears on the decline in high income 
countries, the habit in developing countries appear to be on the ascendancy. The 
rise in population and income in low and middle income countries, has 
subsequently caused an elevation in their smoking tendencies and presently 
constitute a major public health issue4.Hence, the major battleground for the 
global fight against tobacco consumption has shifted from the developed nations 
to the developing nations, particularly India and China.  
 
 
  
THE INDIAN SCENARIO 
 
India has the dubious distinction of being second in the world when it comes to 
tobacco consumption and third in terms of manufacturing of tobacco products 
worldwide. It has also been reported that nearly 900,000 people succumb to 
illnesses related to tobacco per year in India5. Although tobacco can be 
consumed both through smoked and smokeless forms, smoking is reported to be 
the predominant habit among males in India constituting more than 50 % of the 
tobacco users. 
 
 TOBACCO USE IN PATIENTS WITH SEVERE MENTAL DISORDERS 
 
It is suggested that people with mental illness are twice as likely as non 
psychiatric controls to smoke3 and that in the US estimates of smoking 
prevalence among individuals receiving psychiatric care indicate that between 
50% to 80% psychiatric patients smoke,4-6 compared to 24% of the general 
population.7 Some studies show that patients with schizophrenia who smoke 
score higher on psychotic rating scales when compared to their non smoking 
peers.4,8 and that when comparing the severity of psychotic symptoms in 
  
patients with bipolar affective disorder increased severity in patients who smoke 
is seen.9  
 
But research also indicates that nicotine may be particularly effective in 
relieving negative symptoms associated with schizophrenia relative to other 
psychiatric symptoms.10,11 Thus a need to establish clarity regarding the 
association of smoking with severe mental illness appeared vital in the 
treatment of the disorder itself.  
 
Studies in India about nicotine use in psychiatric patients are few and far in 
between. One study done in India among 510 male psychiatric patients, reported 
that the prevalence of smoking was 38% among patients with schizophrenia, 
24% among patients with mood disorders, and 23% among those with a non-
psychotic disorder.12 
 
HOW EFFECTIVE IS NICOTINE REPLACEMENT THERAPY(NRT)? 
 
Studies have given conflicting reports on the effectiveness of nicotine 
replacement therapy on smoking cessation with one concluding that ‘NRT is no 
more effective in helping people stop smoking cigarettes in the long-term than 
trying to quit on one’s own’14 and another study confirmed that nicotine assisted 
  
reduction to stop programmes can be effective in achieving sustained abstinence 
from smoking for up to six months.15 
 
 In controlled trials in smokers with schizophrenia,abstinence rates have been 
4% to 19% at 3- to 6-month follow-up with single preparation NRT and 0% to 
6% with placebo.16 
 
To our knowledge, no study has looked into the effectiveness of nicotine 
replacement therapy in the Indian setup. 
 
Hence a study that looked into the prevalence and severity of nicotine 
dependence in Indian patients suffering with schizophrenia and bipolar disorder 
and following them from acute stage to remission stage seems prudent. We 
provided 3 educational sessions about quitting smoking and Nicotine 
replacement therapy and gave nicotine gums to patients who are willing to try 
and studied its effectiveness. 
 
 
 
 
 
  
REVIEW OF LITERATURE 
 
     The World Health Organisation has given an estimate that nearly 5 million 
deaths occur annually worldwide as a result of tobacco use3. Other than 
smoking, tobacco can also be chewed, inhaled, or applied on oral mucosa with 
the unconventional methods of tobacco consumption finding immense 
popularity in South Asia and South-east Asia. However, worldwide 90 % of 
tobacco consumption is accounted for by cigarettes. 
 
     In addition to cigarettes, beedis appear to be a popular form of smoking 
tobacco. Beedis consist of finely ground, sun – dried tobacco hand rolled in a 
brown, broad leaf locally known as tendu (Diospyrusmelanoxylon or 
Diospyrusebemum). Beedis remain popular, especially among the rural and low 
socio-economic strata given it’s cheaper cost and association with tradition. 
Beedis are said to account for 48 % (750 billion to 1.2 trillion) of tobacco 
consumption in India whereas cigarettes account for 14%, making beedis the 
most preferred form of tobacco consumption among Indians13. 
 
  
Toxicological analysis suggest that the smoke of beedis, like regular cigarettes, 
contain phenol, hydrogen cyanide, and benzo(a)pyrenes6 and total particulate 
matter, a measure directly related to the amount of carcinogenic material7 . Nair 
and colleagues identified carcinogenic tobacco specific nitrosamines from the 
smoke of beedis in concentrations similar to regular cigarettes8. When compared 
to an unfiltered cigarette, beedi smoke contains more tar, carbon monoxide, 
ammonia, hydrogen cyanide, phenol, volatile phenols and benz(a)anthracene. 
 
     13Gutkha and Zarda constitute the main form of tobacco consumption by 
means of chewing. Gutkha is a mixture of crushed areca nut, tobacco and 
catechu, available in both sweet and savoury flavourings. It’s usually chewed 
and spit out. It is commonly used by women and children as well, in a culture 
where smoking by the fairer sex is still looked down upon. Zarda is a dried and 
coloured residual tobacco, obtained by boiling leaves with spices and lime. 
 
      Ever since the publication of the Doll and Hill study of smoking and lung 
carcinoma in 1950, the dire consequences of tobacco consumption have been 
well established. The following years saw several other studies report on the 
adverse effects to health as a result of tobacco consumption. Presently, the 
consumption of tobacco is recognised as a major health hazard and cause for 
  
premature morbidity and mortality across the world. As a result, measures to 
tackle tobacco intake forms the mainstay of all major health programmes across 
the world. 
 
     To look into the epidemic of smoking in India, a study was done by Venkat 
Narayan et al22 in 1996 in Delhi by surveying a random sample of adults that 
were living in urban Delhi. Out of the 13,558 subjects surveyed, 24.5% (95 % 
confidence interval 23.8 to 25.2) were smokers. Men had a significantly higher 
prevalence rate of smoking with 2,799 (45.0%) of the 6,221 male subjects 
studied being smokers. Among the women who were involved in the study only 
516 (7.0%) of the 7,337 women admitted to smoking. 
 
     Subramanian et al23 looked into the patterns and distribution of  tobacco 
consumption in India from the 1998 – 9 national family health survey. The 
analysis included 3,01,984  adults aged 18 and older, from 92,447 households 
from 26 Indian states. The overall prevalence for the consumption of tobacco by 
means of smoking was 18.4 % and for chewing was 21.0 % with a combined 
prevalence of 32.9 %.  
 
  
    In another study conducted at NIMHANS, Bangalore, Chandra et al screened 
consecutive psychiatric patients who got admitted and found that 36% of them 
use some form of tobacco products.13 But both these studies were cross 
sectional studies which didn’t look into the severity of mental illness with 
smoking and didn’t follow up the patients to study any changes in the pattern of 
cigarette use. 
 
     In a study done by Jayakrishnan et al24 in a rural population in Kerala, the 
overall prevalence of current daily smokers was 28.1 % (mean age 44.4 years, 
SD ; 9.2 years). The study design is a community based randomised 
intervention trial in 4 community development blocks in Thiruvananthapuram 
district. Ward is the lowest level of administrative system of community 
development blocks. A total of 11 wards (5 from intervention and 6 from 
control area) were selected from the CDBs using random sampling method. A 
smoking cessation programme was being conducted for those in the intervention 
area. Among the 3,304 males in the intervention and control arm, a total of 928 
‘current daily smokers’ were identified from house to house survey.  
 
     Of the 928 smokers, 474 subjects were in the intervention area (mean age: 
44.56 years, SD: 9.66 years) and 454 in the control area (mean age: 44.47 years, 
SD: 10.30 years). The average number of cigarettes and beedis consumed per 
  
day corresponds to 13.19 (SD: 8.4) in the intervention and 10.90 (SD: 6.8) in 
the control groups. 
 
     Cigarette smoking was the most common habit among both groups 
representing 62.5% in the control and 53.8% in the intervention areas. The 
mean duration of smoking was 15.05 years in the control area (SD: 8.28) and 
15.78 years (SD: 9.09) in the intervention area.  
 
     The overall FTND score among current daily smokers was 5.04 (SD: 5.05). 
FTND scores in the control and intervention areas were 4.75 (SD: 2.57) and 
4.92 (SD: 2.51) respectively. In conclusion, the study reported moderate level of 
nicotine dependence in the rural population in Thiruvananthapuram, Kerala. 
 
     In a study, 26Grant et al estimated the burden of all US tobacco consumption 
carried by nicotine dependent and psychiatrically ill individuals. Among US 
adults, 12.8 % (95 % confidence interval, 12.0 – 13.6) were nicotine dependent. 
Associations between nicotine dependence and specific axis I and II disorders 
were strong and significant (p<0.05) in the total population among both men 
and women.  
 
  
     Nicotine dependent individuals with co-morbid psychiatric disorder 
constituted 7.1% of the population only and yet they consumed 34.2 % of the 
total tobacco consumed in the United States. The authors conclude that patients 
who are nicotine dependent and has a psychiatric disorder would fall into a 
vulnerable category for tobacco consumption and hence de-addiction treatment 
in them needs to be actively pursued. 
 
     A similar study evaluated the findings of the national survey done in Britain 
in 199525. Among those surveyed, 32 % were reported to be current smokers, 
with 8 % classified as light smokers (less than 10 a day), 13 % moderate 
smokers (10 – 20 a day) and 11 % were heavy smokers (more than 20 a day). 
No gender difference in patterns of cigarette smoking was noted unlike among 
the Indian population. Among those who were classed as having psychiatric 
disorder, 33 % (3,329) were classed as having nicotine dependence as well. 
 
      The authors further suggested that there was a clear relationship between 
dependence on nicotine, alcohol and drugs and psychological morbidity. They 
also added that smoking nicotine is associated significantly with increased 
psychiatric disorders.    
 
  
      Studies have shown that the prevalence of smoking is significantly higher 
among psychiatric outpatients than the general population27. The more severely 
afflicted patients like those with schizophrenia and mania, showed high 
prevalence rates of 88% and 70% respectively.  
 
Another study sought to study the prevalence of smoking among French 
psychiatric patients. The prevalence of smoking among 711 patients with 
mental illness was significantly higher than the French general population30 
 
     The relatively high prevalence of nicotine dependency in persons with 
mental illnesses and substance abuse disorders reflects biological, psychosocial, 
and cultural factors in addition to targeting by the tobacco industry. Some 
mental illnesses have associated neurobiological features that increase their 
tendency to use nicotine, make it more difficult to quit, and complicate the 
withdrawal phase of tobacco cessation.  
 
     Genetic linkage studies have found associations between both schizophrenia 
and bipolar disorder and chromosome 15 in a location at the alpha 7-nicotinic 
receptor subunit gene28,29, and the alpha-7 nicotinic receptor gene has been 
implicated in impaired sensory processing in individuals with schizophrenia and 
  
schizoaffective disorder31. Individuals with this gene have auditory sensory-
gating deficits and diminished suppression of the auditory evoked P50 response. 
Nicotine briefly normalizes this deficit, suggesting an association with 
diminished P50 response and decreased alpha-7 subunits of nicotinic receptors 
for persons with these psychiatric illnesses29. 
 
      Gene studies have also found that adolescents with at least one A1 allele 
have increased impairment of dopaminergic functioning, symptoms of 
depression, and smoking32. These genetic linkages and receptor abnormalities 
are one of many factors explaining heavy levels of smoking in these individuals, 
as nicotine might normalize associated deficits in sensory processing, attention, 
cognition and mood29. 
 
      Nicotine may also offer brief relief from medication side-effects, since 
tobacco use significantly decreases blood levels of common psychiatric 
medications8. For persons with substance abuse disorders, tobacco use affects 
the same neural pathway— the meso-limbic dopamine system—as do alcohol, 
opiates, cocaine, and marijuana33. The effects of nicotine and opiates on the 
brain’s reward system are equally potent in a key pleasure-sensing area of the 
brain: the nucleus accumbens34.  
  
      
    Persons with mental illnesses and substance abuse disorders also use tobacco 
for the same reasons as the general population: as part of a daily routine to 
relieve stress and anxiety. Tobacco use is perceived as a way to fit in and to 
cope with boredom when social and vocational options are limited. 
 
     When coming to the management of these patients, unfortunately the culture 
of mental health and substance abuse care reinforces tobacco use in treatment 
settings, residential facilities, and housing35. Mental health and substance abuse 
providers also have high smoking prevalence rates—30%–35% 36— thereby 
impeding tobacco cessation efforts37. By contrast smoking rates among primary 
care physicians are only 1%38. 
 
     
12A study done in India on 286 urban male outpatients with schizophrenia 
showed that only 38% were found to be smoking presently. This was said to be 
significantly more than patients who were studied with other psychiatric 
diagnosis ( major affective disorders and non-psychotic disorders) but not 
medically ill controls and not higher than the rates for the general male 
population in India. In this study, the use of the smokeless form of the tobacco 
  
appeared to be insignificant. The study also reported that more than half of the 
responders reported no positive effects from usage of tobacco. 
 
     
13Chandra et al screened 988 consecutive admissions to a major psychiatric 
hospital in South India. Information was obtained about their use of tobacco 
products, and participated in the Fagerstrom Test for Nicotine Dependence as 
well as measures of other substance use. Three hundred and fifty-one patients 
(36%) reported to be using tobacco currently, with two hundred and twenty 
seven (65% of tobacco consumers) reporting moderate to severe nicotine 
dependence. The major diagnosis among tobacco users was that of bipolar 
affective disorder.  
 
     The authors suggested that the smoking epidemic among the psychiatric 
patients in India has not reached the same level as those in the west. After 
cautioning for difficulties in interpreting cross-cultural variations, the authors 
postulated that a presence of a strong family system in India even for the 
mentally afflicted patients could be a possible explanation for the same. Also, 
restrictions imposed by family and society on smoking and lower income for 
patients to afford tobacco-related products were some of the other reasons 
listed. 
  
 
     A study39 recruited male patients with schizophrenia and their non-psychotic 
brothers. Detailed information about tobacco consumption was obtained 
through Fagerstrom Test for Nicotine Dependence (FTND)for smoked tobacco 
and FTND – smokeless tobacco.  
 
     Investigators also administered University of Pennsylvania Computerized 
Neurocognitive battery (CNB) for a sub-group of patients. Results showed that 
schizophrenia patients began using tobacco earlier than their non-psychotic 
brothers. Also, patients with schizophrenia who were current smokers scored 
higher on positive symptoms of schizophrenia than non-smokers. No significant 
difference between nicotine dependent patients and non dependent patients were 
seen in CNB domains except for attention. 
 
     
40A study in Bangladesh on an urban population of 510 male psychiatric 
patients ( Schizophrenia = 286, Major affective disorders = 84, Non psychotic 
disorder = 140) showed that prevalence of smoking in psychiatric patients is no 
greater, if not lesser, than that of the control group of medically ill patients with 
no psychiatric diagnosis (n=177) or the general population. More number of 
psychiatric patients had reported to have quit smoking than the medically ill. 
  
The reasons for the absence of high prevalence of smoking among the 
psychiatric patients were said to be socio-cultural and economic.  
 
In a study4 done on seventy eight outpatients with schizophrenia, who were 
assessed by a single rater using the Brief Psychiatric Rating Scale (BPRS), it 
was found that current smokers tend to have a younger age of onset, more 
number of previous hospitalisation, require higher mean neuroleptic doses and 
scored higher in the BPRS. The study implicated that smoking adversely 
affected symptoms of schizophrenia. 
 
     A meta-analysis of worldwide studies showed that forty-two of them across 
20 nations consistently showed an association between schizophrenia and 
current smoking with odds ratio (OR) at 5.9, 95% confidence interval (CI) at 
4.9--5.7. Even when controlled for other variables, the association between 
schizophrenia and current smoking patterns remained. Heavy smoking and high 
nicotine dependence were more witnessed in patients with schizophrenia when 
compared to the general population. When compared to the general population, 
patients with schizophrenia had a greater prevalence of having ever smoked a 
cigarette (OR=3.1, CI 2.4--3.8). Further, two studies, when adjusted for 
confounders, showed that patients with schizophrenia showed an increased risk 
  
of smoking everyday compared to control groups. Hence, this study concluded 
that people with schizophrenia have more risk to start smoking. 
 
    In another study, Beck et al41 recruited 16 patients with schizophrenia or 
schizo-affective disorder and 12 community controls participated in 
experimental sessions. Cognitive assessment was done through observations on 
three cognitive indices - visual spatial working memory (VSWM), sustained 
attention (Continuous Performance Test – Identical Pairs – CPT-IP) and 
prepulse inhibition (PPI) after ‘typical’ smoking and overnight abstinence. They 
were compared with self reported smoking motivation (Modified reasons for 
Smoking Scale that included ‘cognitive motivators’). Smokers among patients 
with schizophrenia (but not controls) showed significant less error on the 
VSWM task in the smoking relative to the abstinent condition. Thus, this 
preliminary study showed that differential effects of nicotine on cognition may 
improve the so called negative effects of schizophrenia. 
 
     This study throws an interesting conundrum about the role of nicotine in 
patients with schizophrenia. On the one hand, it’s effects are said to be 
detrimental in schizophrenia, with apparent greater severity of symptoms in 
schizophrenia patients who smoke. On the other hand, nicotine is said to 
  
improve the negative symptoms of schizophrenia and particularly small studies 
have shown enhanced cognitive performance in patients with schizophrenia 
who use nicotine. 
 
     Data from National Co-morbidity Survey done in 92-93 showed that the 
prevalence of smoking in bipolar affective disorder was 69% but a 2007 
National Health Interview Survey suggested a prevalence rate of 46%. A study 
which attempted to address this variability was done by Diaz et al42 by studying 
424 psychiatric patients and 402 volunteer controls at Central Kentucky. Of the 
424 psychiatric patients, 99 were diagnosed as bipolar, 258 had a diagnosis of 
schizophrenia and 67 of major depression. Prevalence of daily smoking patterns 
currently for patients with major depression, bipolar and schizophrenia were 
57%, 66% and 74% respectively.  
 
     Data on smoking in patients with bipolar affective disorder are conflicting, 
with some studies suggesting that bipolar affective disorder patients are prone to 
increased smoking while other studies found that instances of smoking among 
bipolar disorder patients were lesser than previously reported. The reasoning 
behind this was suggested to be that in the latter sample there was a 
preponderance of patients with unipolar depression. It was hypothesised that the 
  
presence of psychotic symptoms was more likely to induce smoking tendencies 
in patients.  
 
     Yet the study found no evidence of a link between the severity of psychosis 
and the severity of smoking, as there was no difference in the severity of 
psychosis between the moderate and heavy smoking groups. This was attributed 
to the insufficient sample size and the relatively small groups that were involved 
making it difficult to distinguish if such a difference existed. 
 
     The relationship with nicotine and bipolar disorder also appears to be 
complex from studies. Some suggest that smoking could lead to depression and 
other affective disorders, with others suggesting that among smokers, cessation 
of smoking has been associated with development of an affective episode. 
 
    
43A review done by Balfour et al suggested that chronic exposure to nicotine 
causes changes in serotonin formation and release in the hippocampus which 
are depressogenic. The authors further postulate that smokers are protected from 
the consequences of the aforementioned impacts, as long as they continue to 
smoke. This is explained through the purported anti-depressant properties of 
nicotine. Further, it is said that these changes contribute to the symptoms 
  
suggestive of depression that smokers go through while attempting to quit the 
habit. 
 
     Hitsman et al44 in their review address the dilemma some psychiatrists might 
face in treating nicotine dependence given the conflicting role of nicotine in 
various studies in reference to psychiatric illness. In their review, the authors 
report that quite often psychiatry care givers do not address the issue of nicotine 
dependence as they feel that their clients might not be able to quit completely or 
might even be adversely affected in their psychiatric status.  
 
     They suggested that not only do psychiatric symptoms not worsen upon 
quitting smoking, some may even improve in their psychiatric symptoms upon 
quitting tobacco. Therefore, the authors concluded that clinicians should not 
refrain from treating the nicotine dependence in patients with comorbid 
psychiatric disorders, but should instead encourage cessation and provide 
support as they would with any other smoker.  
 
     Many mental health and substance abuse providers believe tobacco cessation 
is unrealistic for their clients. Smoking is often seen as one of the last freedoms 
and chances to execute free will in patients with psychiatric illness, making 
  
clinicians apprehensive about pursuing it’s cessation.  Tobacco use is viewed by 
many providers as a lesser problem than the immediate consequences of other 
substance abuse45.  
 
     Despite opinions to the contrary, the smoking cessation rates of persons with 
mental illnesses and substance abuse disorders who desire to quit are 
comparable to the general population46. Several studies have found that 77%–
79% of these individuals intend to quit, many in the next month. Although these 
clients may desire to quit, most are not afforded the same cessation 
opportunities as the general population.  
 
     Behavioural health specialists, in contrast to primary care providers, rarely 
assess for smoking status or provide cessation counselling. Psychiatric patients 
receive cessation counselling in only 38% of their visits to primary care 
physicians and 12% of their visits to psychiatrists47. The situation appears even 
worse in inpatient settings, where—among 250 psychiatric inpatients—only 1% 
were assessed for smoking status, nicotine dependency was not assessed, and 
smoking status was never included in treatment plans. 
 
  
     Providers and administrators warn that forbidding smoking will disrupt the 
treatment milieu, dramatically increase behavioral problems, and result in 
premature or irregular discharges. But, studies from multiple countries did not 
find smoking bans had a negative effect on psychiatric symptoms or 
management in treatment units.  
 
A survey of 158 U.S. state psychiatric facilities found that 41% did not permit 
smoking at their facility or grounds48. Of the remaining 59% still allowing 
smoking, half planned to go tobacco-free in the near future. The sites that had 
gone tobacco-free reported improved health of patients and cleaner 
grounds/environment. Banning smoking reduced seclusion and restraint, 
decreased coercion and threats among patients and staff, and increased 
availability of tobacco cessation medication.  
 
The tobacco industry has long targeted individuals with mental illnesses and 
substance abuse disorders, labelling these populations as “downscale markets.” 
Prochaska49 analyzed tobacco industry documents from 1955 to 2004 and found 
that the industry monitored or directly funded research supporting the concept 
that persons with schizophrenia were less susceptible to the harms of tobacco 
and needed tobacco as self-medication. The industry promoted smoking in 
  
psychiatric settings by providing free cigarettes and aiding efforts to block 
hospital smoking bans. 
 
     A study50 done in the US randomised 123 patients with psychiatric diagnosis 
and who identified themselves as smokers, at 4 community mental health clinics 
at both rural and urban areas. 61 participants were randomised to quitline 
services alone and 62 to both quitline and services of a community tobacco 
cessation group of upto 10 sessions. In addition to this, they received treatment 
as usual for their psychiatric diagnoses and were offered free nicotine 
replacement patches for 12 weeks to all interested participants. Outcome 
measures were administered at baseline and 6-months with results showing a 
50% or greater reduction in smoking and a 10% abstinence rate. This study 
showed the effectiveness of the nicotine replacement therapy. 
 
    In the UK, 51Moore et al did a systematic review and meta-analysis to study 
the effectiveness and safety of nicotine replacement therapy assisted reduction 
to stop smoking. This review found that nicotine assisted reduction to stop 
programmes can be effective in achieving sustained abstinence from smoking of 
six months. Further, they also added that there was no evidence of an increase in 
life threatening complications as a result of nicotine replacement use. The 
  
therapy was well tolerated with almost no difference in discontinuation because 
of side effects in those receiving nicotine replacement therapy compared with 
those receiving placebo. 
 
A randomized study of persons treated in public mental health systems showed 
that quit-line counselling plus nicotine replacement therapy led to a significant 
reduction in self-reported number of cigarettes smoked per day.17  
 
Another randomized study of smokers with mental illness showed that NRT 
was effective in bringing down the self reported number of cigarettes smoked 
per day and tobacco dependency.  
 
18 Cochrane review of over 90 trials found that nicotine replacement helps 
people to stop smoking.19 Overall, it increased the chances of quitting about one 
and a half to two times (1.71, 1.60 to 1.83), whatever may be the level of 
additional support and encouragement.   
    
 
     Another Cochrane review52 on the effectiveness of Nicotine Replacement 
Therapy (NRT) included 136 trials of NRT, with 64,640 people in the main 
  
analysis. It indicated that all forms of NRT studied increased the chance of the 
patient quitting tobacco by about 50 to 60% with or without any counselling. 
The risk ratio (RR) of abstinence of any form of NRT relative to control was 
1.55 with a 95%  confidence interval (CI) of 1.49 to 1.61.  
 
     Hence, nicotine replacement therapy was said to increase the chances of 
quitting by about one and half to two times, irrespective of the manner of 
additional support or encouragement received by the patients. The quit rate was 
higher in both placebo and treatment arms of trials that included intensive 
support. Therefore nicotine replacement therapy seemed to increase the rate of 
quitting from whatever baseline was set by a previous intervention. 
 
      All the trials studied had included at least a brief advice on how to quit 
smoking and hence that was suggested as the minimum additional treatment to 
be offered in addition to the nicotine replacements. 
 
       Meat-analysis of the effect of nicotine replacement therapy on smoking 
cessation showed there was no direct evidence to show that one form of nicotine 
treatment was superior to the other. The odds ratio with 95% confidence 
interval was found to be 1.63 (1.49 to 1.79) for nicotine gums, 1.75 (1.57 to 
  
1.94) in nicotine patches, 2.27 (1.61 to 3.20) in the intranasal spray form of 
nicotine replacement, 2.08 (1.43 to 3.04) in nicotine inhalers, 1.73 01.07 to 
2.80) in sublingual nicotine tablets and 1.71(1.60 to 1.83) among all 
formulations of nicotine replacements. Hence, it was noted that the type of 
nicotine replacement used should be primarily decided by the choice and 
comfort of the patient. This review suggested that no form of NRT was superior 
to the other in addition to showing their general effectiveness and safety in 
smoking cessation. 
 
     Further, a study done by Hajek et al53 compared different forms of nicotine 
replacement in 504 smokers who volunteered for the study. They were 
randomised to 4 groups based on their type of nicotine replacement and 
assessed at quit date, 1, 4 and 12 weeks later. There was no difference noted by 
the authors among the effects the products had on withdrawal discomfort, urges 
to smoke or rates of abstinence. 20%, 21%, 24% and 24% were the continuous 
validated abstinence rates in the gum, patch, spray and inhaler groups 
respectively at 12 weeks. 
 
     In the same study, compliance was shown to be good for nicotine patch, low 
for nicotine gum and very low for the spray and inhaler. The spray appeared to 
  
have lesser than desirable usage as a result of adverse effects, while the less 
usage associated with inhaler was more due to embarrassment.  
 
     The large population-based 54California Tobacco Surveys of 1992, 1996 and 
1999 including 5247 (71.3% response rate), 9725 (72.9% response rate) and 
6412 (68.4% response rate) respondents respectively were studied by Pierce et 
al to look into the long term effectiveness of Nicotine Replacement Therapy. 
Results indicated that NRT use increased short-term cessation success in 
moderate to heavy smokers in each survey year. However, a long-term cessation 
effectiveness among the residents of California appeared to be no greater than 
before.  
 
Thus, the effective of Nicotine Replacement Therapy as a long-term treatment 
option for smoking appears controversial and not substantiated yet. Further, to 
our knowledge, no Indian study on the effectiveness of NRT had yet been 
published which seems critical given the peculiar socio-cultural and economic 
issues related with tobacco consumption in the nation.   
 
 
  
AIMS : 
 
To study the prevalence and severity of smoking among patients with 
schizophrenia and bipolar disorder and also to study the effectiveness of 
nicotine replacement therapy. 
 
OBJECTIVES : 
 
1. To estimate the prevalence of smoking among patients with 
schizophrenia and bipolar disorder. 
2. To study the association of smoking and severity of illness by 
following the patients from acute stage to remission stage. 
3. To prospectively evaluate the effectiveness of Nicotine Replacement 
Therapy (nicotine gums) among smokers in both schizophrenia and 
bipolar disorder groups.  
 
 
 
 
 
  
METHODOLOGY : 
 
Study Design: 
 
This is a prospective and observational study. 
 
Sample Recruitment: 
 
We screened all the male patients admitted in the psychiatry department and we  
recruited consecutive patients who were diagnosed as having schizophrenia or 
bipolar disorder, according to the ICD-10 Classification of Mental and 
Behavioural Disorders criteria 
 
Inclusion Criteria: 
 
     All male patients > 18 years of age with a clinical diagnosis of schizophrenia 
or bipolar affective disorder as per ICD 10 diagnostic criteria who received in-
patient treatment during the period between June 2017 and May 2018 were 
included.  
 
  
Exclusion Criteria: 
 
1. Patients who had co-morbid substance use except alcohol and tobacco. 
2. Patients who had mental retardation. 
 
Materials used in the study: 
 
1. Patient proforma 
2. Brief Psychiatric Rating Scale (BPRS) 
3. Young’s Mania Rating Scale (YMRS) 
4. Hamilton’s Depression Rating Scale (HAM-D) 
5. Fagerstrom Test for Nicotine Dependence – Tamil version (FTND - 
Tamil) 
 
Patient Proforma: 
 
a. Socio-demographic details of the patient 
b. Diagnosis 
c. Clinical details – Duration of illness, number of previous hospitalizations, 
duration of current episode/exacerbation 
d. Details of substance use (tobacco, hans and alcohol) 
e. Smoking details – type of smoking, duration of use, daily usage pattern  
  
f. Nicotine gum use – willingness for nicotine gum, dosage of gum, mean 
number of gums per day, percentage of nicotine gums consumption days, 
continuation at 4th and 12th  week, reason for discontinuation. 
 
Brief Psychiatric Rating Scale (BPRS): 
 
The Brief Psychiatric Rating Scale (BPRS) is a rating scale which a clinician or 
researcher may use to measure psychiatric symptoms particularly in relation to 
psychosis or schizophrenia. It evaluates symptoms like thought content, 
suspisciousness, uncooperativeness, depression, anxiety, hallucinations and 
unusual behaviour. Each symptom is rated 1- 7 and a total of 21 items are 
scored. It was first published in 1962 and is one of the most widely used scale to 
measure psychotic symptoms. 
 
       This scale was used to measure the severity of psychotic symptoms in our 
patient and it was ascertained that they had improved if the score had improved 
>20%. 
 
Young’s Mania Rating Scale(YMRS): 
 
       The Young’s Mania Rating Scale (YMRS) is used frequently to assess 
manic symptoms. It is a clinician rated scale. It takes about 10 to 15 minutes to 
  
administer. The scale consists of 11 items out of which a few of the items are 
rated on a 0 to 8 scale (thought content, irritability, speech  and 
disruptive/aggressive behaviour), while the remaining seven items are graded on 
a 0 to 4 scale. 
 
       This scale was used in our study to assess the symptom severity of manic 
episode and we ascertained that patient had reached euthymic state if the score 
was <6.   
 
Hamilton Depression Rating Scale (HAM-D): 
 
     The Hamilton Depression Rating Scale (HAM-D or HDRS) is also a 
clinician rating scale. It takes 20 to 30 minutes to be administered. It’s 
administration serves the purpose to assess the severity of depressive symptoms 
and also to gauge the difference in depressive symptoms progressively. The 
original version contains 17 items (HDRS17) related to depressive symptoms 
that were experienced in the past week. A 21 item version (HDRS21) included 
four extra items, which is intended to further classify the depression. A 
limitation of this scale is that it does not assess the atypical symptoms of 
depression (e.g. hypersomnia,  hyperphagia) 
 
  
      This scale was used in our study to assess the severity of the symptoms 
occurring in the depressive episode and we ascertained that that patient had 
reached euthymic state if HDRS score <6 in the 17 items scale. 
 
Fagerstrom Test for Nicotine Dependence (Tamil Version): 
 
      The Fagerstorm Test for Nicotine Dependence is a standard instrument used 
to assess the intensity of physical addiction to nicotine. It was designed to 
provide an objective measure of nicotine dependence related to cigarette 
smoking. It has six items that evaluate the quantity of cigarette consumption, the 
compulsion to use and the dependence. 
 
       It was originally developed as the Fagerstrom Tolerance Questionnaire by 
Karl-OlovFagerstrom and modified to the Fagerstrom Test for Nicotine 
dependence by Heatherton et al in 1991. 
 
This scale has been adapted and validated in Tamil, in order to overcome any 
linguistic barriers in the assessment of the severity of nicotine dependence 
among patients in their native language. 
 
We obtained informed consent from the recruited patients and their caregivers. 
At baseline, we measured the severity of the mental illness, using BPRS for 
  
schizophrenia and using YMRS and HDRS for bipolar disorder. Using a semi-
structured proforma we collected the socio-demographic details, clinical data, 
smoking status and number of cigarettes smoked among smokers. Among 
patients who smoke, we used Fagerstrom Test for Nicotine Dependence scale to 
assess the severity of smoking.  
 
To patients who were dependent on smoking, we suggested them to take 
nicotine gum to manage withdrawal symptoms as well as to help in maintaining 
abstinence while in the hospital.  
 
We suggested : Nicotine gum – 2mg 3 per day for those who smoke >10 but 
<20 cigarettes a day and 4 mg 3 per day for those who smoke  ≥20 cigarettes 
per day 
 
As happening with all patients, we expected that patients might or might not 
accept nicotine replacement for various reasons. In our study, we had planned 
to do naturalistic observations among our patient groups to estimate how many 
accepted nicotine replacement and to study the effects on their smoking status. 
 
Once the mental state of the patients improved, we provided 3 educational 
sessions to motivate them to give up smoking and suggested them to take oral 
nicotine replacement for at least 3 months.  
  
 
Educational sessions involved the 5As, evaluating the stage of readiness to 
change and motivational interviewing as per the 2005 NSW Australia Health 
booklet21 
 
The 5 As 
 
 Asking about tobacco use 
 Assessing willingness to change and nicotine dependence 
 Advise on tobacco cessation 
 Assist in tobacco cessation 
 Arrange follow up 
 
Stage of Readiness to Change 
 
     Stage of Change is a valuable model for assessing a person’s readiness to 
change a variety of behaviours including tobacco smoking. Cessation is 
explained as a process rather than a discrete event and smokers cycle through 
the stages of being ready, quitting and relapsing on an average of three to four 
times. Readiness to change can be fluid so some smokers will have moved 
groups when seen at different times. 
 
  
     Key questions to ask are “How do you feel about your smoking at the 
moment?” –  Stage of readiness to change can be assessed by asking this key 
question. Clarify whether the smoker is ready to make a quit attempt at this time 
or in the near future. Ask “Are you ready to quit now?”  
 
     People who smoke broadly fall into the following categories:  
     • Not ready (pre-contemplation) – not seriously thinking of quitting in the 
next 6 months  
     • Unsure (contemplation) – considering quitting in the next 6 months  
     • Ready (preparation) – planning to quit in the next 30 days  
     • Action – people who have quit in the last six months • Maintenance – 
smokers who have been          abstinent for more than 6 months. 
 
    Tailored assistance to the stage of readiness to change is given.  
Not ready group – Show interest and encourage the patient to think about the 
issues  
Unsure – Motivate change and offer help to identify and overcome barriers to 
cessation  
Ready – Provide assistance  
            – to develop a quit plan  
            – Suggest coping strategies 
            – Delay, Deep breathe, Drink water, Do something else  
  
            – Assist with pharmacotherapy where indicated  
            – Encourage social support  
Action – Congratulate on progress 
–  Check for problems and if present advise or refer appropriately  
Maintenance – Congratulate and reinforce benefits of being a non-smoker. 
 
Brief Motivational Interviewing 
 
     Motivational interviewing is a key skill for assisting the unsure group of 
smokers. It involves asking open-ended questions, reflective listening and 
summarising. Ambivalence about smoking (likes and dislikes) should be 
acknowledged and discrepancies in the person’s beliefs and personal goals such 
as health and fitness can be discussed. 
 
     The following approach can be used to explore ambivalence and to motivate 
the patient to consider the need to change. It is important to start with the 
positives of smoking for the patient, as these are frequently not acknowledged. 
 
 Step 1: Ask: “What do you like about smoking?”  
Step 2: Ask: “What are the things you don’t like about smoking?”  
 
Step 3: Summarise – your understanding of the patient’s pros and cons  
  
 
Step 4: Ask: “Where does this leave you now?” This can be used as a written 
take home exercise or during the consultation. Ask the patient to list both their 
likes and dislikes about smoking and their likes and dislikes of quitting. 
 
At the time of discharge, we assessed the severity of illness using BPRS, YMRS 
and HDRS appropriately and we repeated this 4 weeks and 12 weeks after 
discharge from the hospital. We also assessed the smoking status and the 
severity of smoking using Fagerstrom Test for Nicotine Dependence scale 4 
weeks and 12 weeks after discharge from the hospital. Patients who did not 
come for outpatient follow-up treatment, both patients and their caregivers were  
contacted separately over the phone to get the details about their current 
smoking status and adherence to oral nicotine replacement therapy. 
 
Sample size calculation: 
 
Among male psychiatric in-patients, Chandra et al found the prevalence of 
smoking as 44%. Using this estimate, we calculated sample size with the 
formula n=(Z1-α)2(P(1-P)/D2),  keeping confidence interval as 95% and absolute 
precision as 10%; we needed 90 patients to estimate the prevalence of smoking 
among male patients suffering with schizophrenia or bipolar disorder 
 
  
STATISTICAL ANALYSIS 
We carried out the statistical analysis using the software SPSS (IBM SPSS - 
Statistical Product and Service Solutions, version 19.0). We tested for normality 
of all continuous variables using Shapiro-Wilks test. We used descriptive 
statistics to get the mean, median and standard deviation of following 
variables: age, monthly income, duration of illness, duration of current 
episode/exacerbation, number of hospitalization,  scores obtained in the rating 
scales at baseline, IV week and XII week (BPRS, YMRS, HAMD), duration of 
smoking, number of cigarettes/beedis, and score obtained in Fagerstrom 
nicotine dependence test. We got frequencies of the following variables: 
education of patients and their caregivers, marital status, occupation, smoking 
status at baseline, IV week and XII week, number of smokes at baseline, IV 
week and XII week, and number of nicotine gum used per day.   
 
Using chi-square test, we studied the strength of relationship of following 
variables in schizophrenia and bipolar disorder groups:  smoking status at 
baseline, IV week and XII week, willingness to use nicotine gum, and 
compliance with nicotine gum and other medications. We used student t test, to 
study the significance of differences between schizophrenia group and bipolar 
  
disorder group in the following variables: duration of smoking, number of 
nicotine gum used per day, and percentage of nicotine consumption per day.  
 
 
As the variable number of smoke per day was not normally distributed, we used 
Mann-Whitney U test to study the difference in the median of that variable 
between schizophrenia group and bipolar disorder group. As number of smokes 
per day variable was not normally distributed, we used Wilcoxon Signed Ranks 
Test to study the significance of difference between schizophrenia and bipolar 
disorder groups. 
 
 
 
 
 
 
 
 
 
 
  
RESULTS 
 
183 patients admitted 
90 recruited 
- 47 BPAD 
- 43 Schizophrenia 
 
35 Smokers 
- 19 Schizophrenia 
-16 BPAD 
 
28 assessed at IV week 
16 Schizophrenia & 12 BPAD 
7 excluded 
- 4 not contactable 
- 3 discrepancies in data 
26 assessed at XII week 
15 Schizophrenia & 11 BPAD 
9 excluded 
- 6 not contactable 
- 3 discrepancies in data 
 
55 Non Smokers 
- 24 Schizophrenia 
- 31 BPAD 
93 excluded 
- 83 women 
- 5 other subs use 
- 2 MR 
  
 
During our study period from June 2017 to May 2018, 183 patients were 
admitted in our ward for schizophrenia or bipolar disorder. Ninety of those met 
our inclusion criteria and hence was included in our study. Twelve among the 
90 patients did not come for follow up and they were contacted over the phone 
and details about their smoking status and use of nicotine gums were obtained. 
Four participants at 4th week and 6 at 12th week were unreachable and hence not 
included in the data. We have made errors in entering data in 3 participants; 
hence they were excluded from the analysis.  
 
Among 90 patients, 43 were diagnosed to have schizophrenia and 47 were 
suffering from bipolar affective disorder(46 patients were admitted for manic 
episode and one patient was admitted for depressive episode). The mean age of 
the participants with schizophrenia was 39.49 (SD – 9.740) years and that of 
those with bipolar affective disorder was 39.53 (SD – 12.34) years.  
    
      
 
 
 
 
  
Table 1. Socio-demographic profile of patients with Schizophrenia and Bipolar 
Affective Disorder 
BPAD - Bipolar Affective Disorder                   SD Standard Deviation 
 
 
 
 Schizophrenia 
N=43 
BPAD 
N=47 
 
Age in years 
Mean (SD) 
 
 39.49 (9.740) 39.53 (12.337) 
Family  Income 
in rupees 
Mean ( SD) 
 
 16,465.12 
(8,732.394) 
25,531.91 
(14,555.518) 
Education 
N (%) 
I to V 
 
6 (14 %) 5 (10.6%) 
V to X 
 
13 (30.2%) 11 (23.4%) 
Higher Secondary 
 
17 (39.5%) 16 (34.0%) 
Graduate 
 
7 (16.3%) 15 (31.9%) 
Marital Status 
N (%) 
Unmarried 
 
18 (41.9%) 12 (25.5%) 
Married 
 
16 (37.2%) 29 (61.7%) 
Separated 
 
9 (20.9%) 6 (12.8%) 
Occupation 
N (%) 
Unemployed 
 
22 (51.2%) 3 (6.4%) 
Unskilled 
 
13 (30.2%) 16 (34.0%) 
Skilled/Professional 
 
8 (18.6%) 28 (59.6%) 
  
Table 1 presents the socio-demographic profile of the male patients admitted in 
our ward.  
 
    The monthly family income of patients with schizophrenia had a mean of 
16,558.14 (SD – 8688.532) and the mean of the monthly family income among 
patients with bipolar affective disorder was 25,404.26 (SD - 14,678.674). 
 
     Majority of the patients with schizophrenia fell into the secondary to higher 
secondary category in education while among the bipolar disorder patients, 
most had done their higher secondary or graduation. 
 
 When looking into the marital status of the participants, most [41.9%(n=18)] of 
the patients with schizophrenia were unmarried while a majority [61.7% 
(n=29)] of those with bipolar affective disorder were married. 
 
     More than half, 51.2%(n=22) of the schizophrenia patients were 
unemployed. Unskilled form of employment was being done by 30.2%(n=13) 
among the schizophrenia subset while 34.0%(n=16) of the bipolar disorder were 
  
engaged in unskilled labour. 59.6%(n=28) were involved in skilled or 
professional line of work for the bipolar affective disorder group.     
 
Table 2. Severity of illness among patients with Schizophrenia and Bipolar 
Affective Disorder 
 
 Schizophrenia Mean  
(SD) 
 
BPAD Mean (SD) 
Duration of Illness 
(years) 
 
14.19(8.063) 12.89 (9.286) 
Duration of Current 
Episode (weeks)  
 
9.86 (6.472) 5.15 (3.155) 
Number of Previous 
Hospitalisations 
 
1.95 (1.731) 1.85 (1.351) 
Number of Previous 
Hospitalisations 
 
1.95 (1.731) 1.87 (1.361) 
BPAD- Bipolar Affective Disorder                     SD- Standard Deviation 
 
     The duration of illness appeared to be long in both the groups with mean 
duration of illness in years being 14.19(SD – 8.063) years for patients with 
schizophrenia and 12.89(SD – 9.286) years for those with bipolar affective 
disorders. The mean duration of the current exacerbation was 9.86(SD – 6.47) 
weeks for patients with schizophrenia and the mean duration of the current 
  
episode was 5.15(SD – 3.16) weeks for the bipolar affective disorder patients. 
The number of previous hospitalisations appeared to be similar across the two 
groups with the mean being 1.95(SD-1.731) in the schizophrenia section and 
1.87(SD-1.361) in the bipolar affective disorder section.    
 
Table 3. Baseline data of patients with Schizophrenia and Bipolar Affective 
Disorder 
 
 Schizophrenia Mean 
(SD) 
 
BPAD Mean (SD) 
BPRS *(Baseline) 
n=43 
28.90  (3.987) 
 
- 
YMRS# (Baseline) 
n=46 
- 
 
37.26 (2.970) 
HAMD^ (Baseline) 
n=1 
- 
 
22.00 
BPRS (4th week) 
n=12 
8.10 (4.175) 
 
- 
YMRS (4th week) 
n=10 
- 
 
6.38  (5.755) 
HAMD (4th week) 
n=0 
- 
 
- 
BPRS (12th week) 
n=11 
5.56  (2.651) 
 
- 
YMRS (12th week) 
n=9 
- 
 
3.38 (4.955) 
HAMD (12th week) 
n=0 
- 
 
- 
*Brief Psychiatric Rating Scale                      BPAD -Bipolar Affective Disorder 
  
#Young’s Mania Rating Scale                         ^Hamilton’s Depression Rating 
Scale 
SD Standard Deviation 
 
      The mean baseline score on the Brief Psychiatric Scale among 
schizophrenia patients gradually improved over 12 weeks. The mean baseline 
score on the Young’s Mania Rating Scale improved from 37.26(SD-2.970) to 
3.38(SD-4.955) at 12th week. There was only a single bipolar affective disorder 
patient admitted with a depressive episode and his HAMD baseline score was 
22.  
 
 
 
 
 
 
 
 
  
Table 4. Details of smoking among patients with Schizophrenia and Bipolar 
Affective Disorder 
 
  Schizophrenia 
N=43 
 
BPAD 
N=47  
Total Statistics 
Schizophrenia 
Vs BPAD 
 
Smoking 
Status 
N (%) 
Yes 19 (44.2%) 16 (34.0%) 35 
(38.9%) 
 
X²(1) = 0.972  
P = 0.324 
No 24 (55.8%) 31 (66.0%) 55 
(61.1%) 
 
Duration 
of 
Smoking 
in years 
Mean  SD 
 18.79 (8.772) 16.06(9.270)  t(33) = 0.893 
p = 0.378 
 
Type of 
Smoking 
N (%) 
Cigarettes 10 (52.6%) 9 (56.3%) 
 
19(54.3%)  
Beedis 6 (31.6%) 4 (25.0%) 
 
10 
(28.6%) 
 
Both 3 (15.8%) 3 (18.8%) 
 
6 (17.1%)  
No. of 
cigarettes 
Mean 
(SD) 
 
 10.58 (6.487) 12.75 
(8.092) 
11.67 
(7.257) 
 
No. of 
beedis 
Mean(SD) 
 
 8.22 (5.178) 12.43 
(13.501) 
10.06 
(9.747) 
 
No. of 
smokes 
Median 
 
 10.00 12.00 10.00 Z  = -1.384 
p  = 0.166 
Other Hans 4 (9.3%) 2 (4.3%) 6 (6.7%)  
  
substances 
N (%) 
 
Alcohol 
 
7 (16.3%) 7 (17.0%) 14 
(16.7%) 
 
Both 
 
- 2 (4.3%) 2 (2.2%)  
FTND 
 Mean 
(SD) 
 
 3.06 (2.772) 3.86  (2.445)  t(29)=-841 
p=0.407 
X² Pearson Chi Square Test                    BPAD Bipolar Affective Disorder                     
t T test                                                       Z Mann Whitney Test 
SD Standard Deviation                           FTND Fagerstrom Test for Nicotine 
Dependence  
 
     Of all the schizophrenia patients evaluated, 44.2%(n=19) identified 
themselves as smokers and 34.0%(n=16) of the bipolar affective disorder 
patients were known to be smokers. Although, the number was slightly lesser in 
the bipolar affective disorder group, the difference was not statistically 
significant (p=0.324). The mean duration of smoking also didn’t differ among 
the 2 diagnostic groups (p=0.378).  
 
      Cigarettes appeared to be the predominant mode of smoking tobacco with 
52.6%(n=10) of patients with schizophrenia and 56.3%(n=9) of patients with 
bipolar affective disorder reported to be using them. 
  
     The median of number of smokes was lesser in the schizophrenia group at 
10.00 as compared to 12.00 for bipolar affective disorder group but the 
difference was not statistically significant(Z=-1.384,p=0.166). 
 
     9.3%(n=4) patients with schizophrenia admitted to using hans as well, while 
16.3%(n=7) of them reported to alcohol use as well. 4.3%(n=2) of the recruits 
with bipolar affective disorder reported using hans as well, with a similar 
percentage reporting using both hans and alcohol in addition to smoking. 
17%(n=7) of the bipolar affective disorder patients had alcohol use as well. 
 
     At the baseline, Fagerstrom Test for Nicotine Dependence had a mean of 
3.06(SD-2.772) for schizophrenia patients and 3.86(SD-2.445) for bipolar 
affective disorder patients. 
 
 
 
 
 
 
  
Table 5. Details of NRT at Baseline 
 
 Total 
N=35 
Schizophrenia 
N=19 
BPAD 
N=16 
Statistics 
Schizophrenia 
Vs BPAD 
 
Wiiling for 
NRT 
N (%) 
 
24 (68.6%) 13 (68.4%) 11 (68.8%) X²(1)= 0.00 
P = 0.983 
Not willing 
for NRT N 
(%) 
 
11 (31.4%) 6 (31.6%) 5 (31.3%)  
Mean no. of 
nicotine gums 
per day  
Mean( SD) 
 
1.92 (0.88) 1.85 (0.97) 2.00 (0.78) t(22)=-436 
p=0.667 
% of nicotine 
consumption 
days Mean 
(SD) 
 
90.02(20.32) 87.82  (24.68) 92.64  
(14.31) 
 
No. of 
patients who 
used 2mg 
Nicotine gum 
N (%) 
 
17 (70.8%) 10 (76.9%) 7 (63.6%)  
No. of 
patients who 
used 4mg 
Nicotine gum  
N (%) 
 
7 (29.2%) 3 (23.1%) 4 (36.4%)  
X² Pearson Chi Square Test         SD Standard Deviation 
  
 BPAD Bipolar Affective Disorder    
 
     Majority of the patients were willing for nicotine replacement therapy across 
the two groups – 68.4%(n=13) of people with schizophrenia and 68.8%(n=11) 
of patients with bipolar affective disorder.  
 
    The mean number of nicotine gums used per day was 1.85(SD-0.97) for 
schizophrenia patients and 2.00(SD-0.78) for those with bipolar affective 
disorder. The percentage of nicotine consumption days was high for both the 
groups, 87.82 (SD-24.68) for patients with schizophrenia and 92.64(SD-14.31) 
for patients with bipolar affective disorder. Most of the patients, 76.9%(n=10) 
and 63.6%(n=7) in schizophrenia and bipolar affective disorder respectively, 
required only 2mg dosage of nicotine gums.  
 
 
 
 
 
 
  
Table 6. Abstinence at 4th week 
 
 Total 
N=28 
Schizophrenia 
N=16 
 
BPAD 
N=12 
Statistics 
Schizophrenia 
Vs BPAD 
 
Abstinent 
N(%) 
10 (35.7%) 3 (18.8%) 
 
 
7 (58.3%) X²(1)= 3.590 
P = 0.058 
 
Not abstinent 
 N (%) 
 
18 (64.3%) 13 (81.2%) 5 (41.7%)  
No of smokes 
Mean (SD) 
 
6.08 (5.60) 7.27 (5.96) 4.30 (4.76)  
No. of 
cigarettes 
Mean (SD) 
 
4.55 (4.92) 4.82 (5.04) 4.22 (5.04)  
No. of beedis 
Mean (SD) 
 
5.08 (5.99) 7.00 (6.41) 1.25 (2.50)  
FTND (4th 
week) 
Mean (SD) 
 
2.61 (2.33) 2.80 (2.44) 2.38 (2.33) t(16)=0.375 
p=0.713 
X² Pearson Chi Square Test                   SD Standard Deviation         NRT 
Nicotine Replacement Therapy 
 
  
 
 
  
Fig 1 Abstinence at 4th week    
 
 
 
 
      Out of the 28 smokers, who were followed up and evaluated at 4th week, 
35.7% were abstinent, with 18.8%(n=3) of the schizophrenia patients and 
58.3%(n=7) of the bipolar affective disorder patients. More number of patients 
in the BPAD group remained abstinent than in the schizophrenia group, which 
showed a trend towards statistical significance (X²(1)=3.590,p=0.058). The 
mean number of smokes was 6.08(SD-5.60) among all patients followed up, 
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with it being 7.27(SD-5.96) among those with schizophrenia and 4.30(SD-4.76) 
for those with bipolar affective disorder.  
 
    Table7. Compliance to NRT at 4th week 
 Total 
N=28 
 
Schizophrenia 
N=16 
BPAD 
N=12 
Statistics 
Schizophrenia 
Vs BPAD 
 
Continuing 
NRT 
N (%) 
 
13 (61.9%) 6 (50.0%) 7 (77.8%) X² (1)= 1.683 
P = 0.195 
Discontinued 
NRT N (%) 
 
8 (38.1%) 6 (50.0%) 2 (22.2%)  
 
 
     Among the smokers,61.9%(n=13) of patients continued nicotine 
replacements, with 50.0%(n=6) of them in the schizophrenia group and 
77.8%(n=7) in the bipolar affective disorder group. This difference was not 
statistically significant (X²(1)=2.561,p=0.110). 
 
    The mean Fagerstrom nicotine dependence scale remained similar between 
the two groups and it was not statistically significant (t(16)=0.375,p=0.713).  
 
  
Table8. Regularity to follow up and medication at 4th week  
 Total 
N=28 
 
 
Schizophrenia 
N=16 
BPAD 
N=12 
Statistics 
Schizophrenia 
Vs BPAD 
Regular to 
Follow up 4th 
week 
N (%) 
 
19 (67.9%) 11 (68.8%) 8 (66.7%) X2(1)=.014 
P=0.907 
Compliant 
with 
medication 
4th week 
N(%) 
 
26 15 (94.1%) 11 (92.9%) X2(2)=1.473 
P=0.479 
 
 
     Both showed similar compliance and follow up rates as well, with the results 
being statistically similar (X2(1)=.014,p=0.907; X2(2)=1.473,p=0.479). 
 
 
 
 
 
 
  
Table 9.    Abstinence at 12thweek 
 Total 
N=26 
Schizophrenia 
N=15 
 
BPAD 
N=11 
Statistics 
Schizophrenia 
Vs BPAD 
 
Abstinent N 
(%) 
 
11(42.3%) 4 (26.7%) 7 (63.6%) X²(1) = 3.554 
p=0.059 
Non 
abstinent 
N(%) 
 
15 (57.7%) 11 (73.3%) 4 (36.4%)   
Number of 
smokes 12th 
week  
Mean (SD) 
 
7.11 (6.57) 7.73 (5.71) 6.25 (7.91)  
FTND (12th 
week) 
Mean (SD) 
 
1.94 (2.04) 2.36  (1.912) 2.00  (2.867)  
X² Pearson Chi Square Test    BPAD Bipolar Affective Disorder      
Z Mann Whitney Test                             SD Standard Deviation 
FTND Fagerstorm Test for Nicotine Dependence 
 
 
 
 
 
  
Fig 3. Abstinence at 12th week 
 
 
     42.9%(n=9) of all patients followed up were abstinent, of which 63.6% were 
from the bipolar affective disorder group and 26.7% from the schizophrenia 
group. More abstinence rate in the BPAD group than the schizophrenia group is 
showing a trend towards statistical significance (X²=3.554,p=0.059). 
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     The score on Fagerstrom Nicotine Dependence Scale also remained similar 
between the two groups at 2.36(SD-1.912) for schizophrenia patients and 
2.00(SD-2.867) for patients with bipolar affective disorder 
 
     Table10. Continuing NRT at 12th week 
 Total 
N=26 
 
Schizophrenia 
N=15 
BPAD 
N=11 
Statistics 
Schizophrenia 
Vs BPAD 
Continues 
NRT 12th 
week N(%) 
 
9 (42.9%) 3 (25.0%) 6 (66.7%) X²(1) = 3.646 
p = 0.056 
Discontinued 
NRT 12th 
week N(%) 
12 (57.1%) 9 (75%) 3 (33%)  
NRT Nicotine Replacement Therapy 
 
     66.7% of the patients with bipolar affective disorder continued their nicotine 
replacement therapy while only 25.0% of the schizophrenia patients and this 
difference was statistically significant(X²=5.239,p=0.0022). 
 
 
 
 
 
  
Table 11. Regular to follow up and medication at 12th week 
 Total 
N=26 
 
Schizophrenia 
N=15 
BPAD 
N=11 
Regular to 
Follow up 
12th week  
N(%) 
 
16 (59.3%) 9 (56.3%) 7 (63.6%) 
Complaint 
with 
medication 
12th week 
N(%) 
 
22 (81.5%) 13 (81.3%) 9 (81.8%) 
 
     A majority(59.3%) of our patients were regular to follow up with 
56.3%(n=9) of the schizophrenia patients and 63.6%(n=11) of the bipolar 
affective disorder patients. Around 80% of our total patients were complaint 
with our medication and the figure was similar among our schizophrenia and 
bipolar disorder group patients. 
 
 
 
 
 
  
Table 12. Effectiveness of NRT: Patients on NRT vs Patients not on NRT at 4th 
and 12th week 
 
NRT Abstinent Not abstinent Statistics 
On NRT 4th week 7 (53.8%) 6 (46.2%) X2(1)=3.590 
p=0.058 
Not on NRT 4th 
week 
1 (12.5%) 7 (87.5%)  
On NRT 12th week 8 (88.9%) 1 (11.1%) X2(1)=10.755 
p=0.01 
Not on NRT 12th 
week 
2 (16.7%) 10 (83.3%)  
NRT Nicotine Replacement Therapy 
 
     Among those who continued NRT at 4th week, half [53.8%(n=7)] remained 
abstinent while a majority [87.5%(n=7)] of those who were not on NRT 
continued to smoke. These results were trending towards 
significance[X2(1)=3.590,p=0.058].  At 12th week, nearly 90%(n=8) of those on 
NRT remained abstinent while 83.3% of those who were not on NRT continued 
  
to smoke. This result was found to be highly statistically significant 
[X2(1)=10.755,p=0.01]. 
 
Fig 2. NRT vs Abstinence at 4th and 12th  week  
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Table  13. Comparison of the number of smokes from baseline to 12th  week 
 
Number of 
smokes 
 
Mean (SD) Median Statistics 
4th week Vs 
Baseline, 12th 
week Vs Baseline 
Baseline 
 
12.82 (7.96) 10.00  
4th  week 
 
 
6.08 (5.60) 5.00 Z = -3.519 
P < 0.0001 
12th  week 
 
 
7.11 (6.56) 5.00 Z = -2.498 
P = 0.013 
Z Wilcoxon Signed Ranks Test                     SD Standard Deviation 
 
     The mean number of smokes at baseline was 12.82(SD-7.96) for all patients 
who were smoking,  which at 4th week was at 6.08(SD-5.60). At 12th week the 
mean was at 7.11(SD-6.56). Both at 4th and 12th week, number of smokes had 
reduced statistically significantly as compared to baseline. 
 
 
 
 
 
  
Fig 3. Mean number of smokes in baseline, 4th and 12th week 
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DISCUSSION: 
     Among the 90 patients whom we recruited for our study, the prevalence of 
smoking was 38.9%. While the prevalence of smoking was 44.2% in 
schizophrenia group, it was 34% for patients with bipolar affective 
disorder group. At 4th week, 58.3% of the bipolar affective disorder patients 
were abstinent as compared to 18.8% of schizophrenia patients and this result 
was heading towards statistical significance (X²(1)= 3.590,P = 0.058). Similarly 
at 12th week, 63.6% of the bipolar affective disorder patients and 26.7% of 
schizophrenia patients were abstinent and this difference was showing a trend 
towards statistical significance (X²(1) = 3.534,P  = 0.059).  The median 
number of smokes reduced from 10 at baseline to 5 at 4th week and to 5 at 
12th week and this reduction was statistically significant. While analysing the 
effectiveness of NRT, comparing to patients who were not on NRT, 53.8% of 
those who were on NRT at the 4th week and 88.9% of those who were on 
NRT at 12the week were abstinent and this was statistically significant.  
 
     In our study, the rates of tobacco use across the sample was 38.9% which is 
similar to the 36% rate of tobacco use among psychiatric in-patients in the study 
conducted by Chandra et al at NIMHANS, Bangalore13. 44.2% of the male 
schizophrenia patients admitted had tobacco use while 34.0% of the patients 
  
with bipolar affective disorder had reported to be using tobacco. In another 
study12 done in India, 38% of the recruited urban male outpatients with 
schizophrenia reported to have tobacco use, which is similar to our findings.  
 
     While the NIMHANS study evaluated tobacco use in both the smoked and 
smokeless form, our study was primarily focussed on the smoking type of 
tobacco use alone. While their study evaluated tobacco use among both sexes, 
we assessed tobacco use in male patients alone. Yet both our studies had a 
similar total prevalence of smoking indicating that perhaps tobacco use in 
females continues to be much below the male population.  
 
       Our study findings and that of similar studies in India would suggest that 
smoking among psychiatric patients is at a rate higher than that of the general 
population. This is in much lesser than the findings of studies in the west, with 
one study27 reporting a prevalence rate of smoking at 88% in schizophrenia and 
76% in mania. Another study30 from France also reported that smoking among 
psychiatric patients were at a rate higher than the general French population. 
 
     In the study23 done by Subramanian et al the overall prevalence of smoking 
all over India was said to be at 18.4 % while the combined prevalence of 
  
tobacco use (including smokeless tobacco) was at 32.1%. This would suggest 
that smoking is perhaps  more prevalent among patients with major mental 
disorders.  
 
     However, these results need to be interpreted with caution, as the above 
mentioned study was done from a survey conducted nearly 20 years ago. 
Further, our study was concentrated in a city in Tamil Nadu while the 
aforementioned study looked into overall prevalence across the nation. India 
being a diverse country with socio- economic and cultural differences across 
states, a comparison between a highly localised population and that of the whole 
nation would seem difficult. 
 
    In a more recent study24 done in rural Kerala, the overall prevalence of 
smoking among males surveyed was at 28.1%. Hence, these studies would 
suggest that smoking may be slightly more prevalent than the general 
population among patients with major mental disorders but the proportion is 
much lesser than what is experienced in the developed world. 
 
     This would suggest that the ill of smoking among psychiatric patients in 
India has not reached the same magnitude as in the west. This finding is perhaps 
  
extendable to other developing nations too, as a study from Bangladesh40 
concluded that smoking among psychiatric patients was no greater, or even 
lesser than that of the general population. 
 
     The reason for this difference could be socio-cultural and economic. Firstly, 
in developing nations like India, a good family support system exists for the 
psychiatric patients. Secondly, a social taboo related to smoking still persists in 
such developing nations, where that habit is frowned upon and even 
discouraged, perhaps unlike the west where individual choice attains primacy. 
Thirdly, most of our patients might still find the cost of the tobacco products to 
be prohibitive and hence is unable to indulge in the behaviour. 
 
     Our study neither showed any relation between the diagnosis and smoking 
status nor duration of smoking with the illness. This is again in contrast with a 
study done in the west which showed a greater duration of smoking among 
schizophrenia patients. The number of smokes had per day also was not affected 
by the diagnosis of the patient. The severity of nicotine dependence also 
appeared to be similar across the two groups as measured by the Fagerstrom test 
for nicotine dependence.  
 
  
     Most of our patients reported mild to moderate nicotine dependence which is 
in contrast to the study13 done by Chandra et al where 65% of the patients were 
in the moderate to severe nicotine dependence range. The contradiction could be 
as a result of a numerous factors. We used a modified Tamil version of the 
Fagerstrom test for nicotine dependence that has been validated as well while in 
their study the test was clinician administered instead of self reported like ours. 
In the study24 done by Jayakrishnan et al in Kerala, the severity of nicotine 
dependence was reported to be of mild to moderate dependence which is similar 
to our study. In their study too, the Fagerstorm test for nicotine dependence was 
translated into the local language and then re-translated to English to check for 
accuracy. Although, we expected a higher severity of nicotine dependence in 
samples with self reportage, perhaps patients were under reporting their levels 
of dependence.  
 
     Also, the Chandra et al study13 modified the Fagerstrom test for nicotine 
dependence to look into the severity of dependence in the smokeless form as 
well but this modification though innovative has not been validated to our 
knowledge.  
 
  
    No relationship was seen between diagnosis (schizophrenia and bipolar 
affective disorder) and willingness to start nicotine replacement therapy. At 4th 
week, 58.3%(n=7) of the bipolar affective disorder patients and 18.8%(n=3) of 
the schizophrenia group were abstinent. This increase abstinence rate in bipolar 
group was trending towards significance (X2 = 3.590,p=0.058).  
 
     Similalry more patients with bipolar affective disorder (63.6%) than patients 
with schizophrenia (26.7%) were abstinent at the end of 12th week as well and 
this difference also moving tending towards statistical 
significance.(X2=3.554,p=0.059).    
     
     More abstinence rate in bipolar disorder could be attributed to the remission 
of manic phase as it is generally seen that patients initiate and indulge in 
smoking during this phase. However, the duration of smoking was similar in 
both the groups suggesting chronic addiction.  Perhaps education about smoking 
cessation and NRT has helped more for our bipolar disorder patients than 
schizophrenia patients.  
       
      Discontinuation of nicotine replacement therapy was seen more in patients 
with schizophrenia than in bipolar affective disorder. Some of the reasons given 
  
for discontinuation was strong burning taste of the gum, headache, nausea and 
hiccups.  This was despite the chew and park technique being taught to all 
patients on nicotine gum. Further, upon changing the flavour of the nicotine 
gum certain participants reported improvement in the burning sensation.  
      
     The mean number of smokes per day showed a statistically significant 
reduction when evaluated both at 4th week and at 12th week. This reduction 
shows that nicotine replacement therapy is effective in reducing the frequency 
of smokes even at the 4th week which is in keeping with a study done in the US 
which shows that nicotine replacement therapy is effective in reducing the 
severity of smoking immediately15. 
 
    Abstinence rates were higher in our study – 53.8%(n=7) and 88.9%(n=8)  for 
patients among both samples who continued nicotine replacement therapy at 
both 4th week and 12th week. Among those who discontinued at 4th week, only 
12,5%(n=1) patient was abstinent and the number was 16.7%(n=2) at 12th week. 
These values were trending towards statistical significance for 4th week [X2 
(1)=3.590,p=0.058] and  significant for 12th week [X2 (1)= 10.755, p=0.01]. As 
all patients received 3 educational sessions irrespective of their compliance to 
nicotine gum, it is fair to assume the added benefit of nicotine gum in addition 
  
to educational sessions. Further as suggested by Thorndlike et al47 nictoine 
replacement therapy is more effective in helping patients remain abstinent if had 
over a three month period.  
      
     Further schizophrenia patients may find it harder to quit smoking completely 
perhaps due to the nicotine improving attention deficits seen as suggested by 
Vats et al study39 done in the US.  There was no difference between the two 
groups when it came to regularity of follow up and medication, suggesting that 
it had no role to play in the results. 
 
 
 
 
 
 
  
STRENGTHS: 
 
1. To our knowledge, this is the first prospective study done on smoking in 
India. All other previously done studies on smoking among psychiatric 
patients in India were cross – sectional studies. This allowed us to have a 
better understanding of the patterns of cigarette use from acute to 
remission stage of the illness. 
 
2. We used a Tamil version of the Fagerstrom Nicotine Dependence Scale 
which has been validated and locally adapted. This allowed us to 
overcome the linguistic barriers that would have risen in the self reporting 
of the severity of nicotine dependence. Previous studies have used the 
English version of the Fagerstom Test for Nicotine Dependence and 
administered by a clinician. 
 
3. We sought to look into the effectiveness of the nicotine replacement 
therapy in a natural setting. This would provide better clinical 
understanding of the role of nicotine replacement therapy in stopping 
nicotine usage. This plays a major role in countries like India where the 
cost remains a crucial factor in stopping certain medications. 
  
LIMITATIONS: 
 
1. Our study was limited to an urban tertiary setting and may not represent 
the whole population. 
 
2. We studied only male psychiatric patients 
 
3. We didn’t analyse the severity of nicotine dependence in those using 
smokeless means of tobacco consumption. 
 
4. Less focus was given on the psychological technique involved in quitting 
smoking 
 
5. We relied on self report to assess smoking and didn’t have an objective 
measure for smoking like conitine level 
 
6. We relied on care giver report for regularity of medication. 
 
7. We didn’t compare effectiveness of nicotine gum across brands or 
flavours. 
 
 
  
CONCLUSION: 
 
Our study highlights various important findings about the prevalence of 
smoking in patients with schizophrenia and bipolar affective disorder and the 
effectiveness of nicotine replacement therapy 
 
1. The prevalence of smoking among male schizophrenia and bipolar 
affective disorder patients is higher than the general population, yet 
lesser than the rates of smoking reported among patients with mental 
illness  in the west. 
 
2. Effectiveness of nicotine replacement therapy in causing abstinence 
from smoking appeared to be more at the 12th week although an 
immediate reduction in the frequency of smoking was seen at the 4th 
week itself. 
 
3. Abstinence from smoking seemed more possible in patients with 
bipolar affective disorder than those with schizophrenia. 
 
 
  
FUTURE DIRECTIONS: 
1. To have studies with higher sample size 
 
2. To measure nicotine dependence among patients with the smokeless 
variety of tobacco consumption as well. 
 
3. To follow up patients for a longer duration of time to check if the effects 
of nicotine replacement therapy are beneficial in the long run as well. 
 
4. To compare effectiveness of other forms of nicotine replacement therapy 
in a naturalized setting. 
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PROFORMA 
Name :                                                                       OP No :      
 Age :                                                                           IP No :        
Sex : 
Education : Illiterate/1 – V grade/V – X grade/Higher Secondary/Graduate/Postgraduate 
Marital status: Unmarried/Married/Divorced or Separated/widow/er  
Occupation: Unskilled/skilled/professional/unemployed 
Total monthly income (in rupees): 
Diagnosis: 
Duration of smoking (in years): 
Type of smoking (cigarette/beedi/both): 
No.of .cigarettes/beedis per day: 
Any other substance use: Hans/Betel nut/ Alcohol 
Willing for NRT :  
 Baseline 4 weeks 12 weeks 
BPRS/YMRS/HDRS  
 
   
Severity of smoking 
as per 
Fagerstrom Rating 
scale 
   
 
Mean number of nicotine gums : 
% of nicotine consumption days : 
Number of Educational Sessions : 1) 
                                                             2) 
                                                             3) 
 
 
  
                                                                     4
th
 week                                     12
th
 week 
Abstinent from smoking 
If no, no. of cigarettes/day 
No. of beedis/day 
Continuing NRT 
If no reason for discontinuing 
Regular to follow up 
Regular on medication 
 
 
 
 
 
 
 
 
 
 
 
 
  
PSG Institute of Medical Science and Research, Coimbatore 
Institutional Human Ethics Committee 
INFORMED CONSENT FORMAT FOR RESEARCH PROJECTS 
(strike off items that are not applicable) 
 
 
I (write name of the investigator(s) here), Dr.Vineet Sukumar 
am carrying out a study on the topic: Prevalence and Severity of Nicotine Dependence on Patients with 
Schizophrenia and Bipolar Affective Disorder and the Effectiveness of Nicotine Replacement Therapy – An 
Observational Study 
as part of my / our research project being carried out under the aegis of the Department of: 
(Applicable to students only): My / our research guide is: Dr.G.Raghuthaman 
The justification for this study is: 
 
The objectives of this study are: 
Primary objectives: 
1. To study the prevalence and severity of smoking among patients with schizophrenia 
and bipolar disorder and also to study the effectiveness of nicotine replacement therapy. 
 
Secondary objectives: 
1. To study the association of smoking and severity of illness by following the 
patients from acute stage to remission stage. 
 
Sample size:. 90 
Study volunteers / participants are (specify population group & age group): 
Location: PSG Hospital, Peelamedu. 
We request you to kindly cooperate with us in this study. We propose collect background information and 
other relevant details related to this study. We will be carrying out: 
Initial interview (specify approximate duration): 45 minutes. 
Data collected will be stored for a period of 3 years. We will / will not use the data as part of another study. 
Health education sessions: Number of sessions: 3 
Clinical examination (Specify details and purpose): Nil 
Blood sample collection: Specify quantity of blood being drawn: _ml : Nil 
No. of times it will be collected: _______________. 
Whether blood sample collection is part of routine procedure or for research (study) purpose: 
1. Routine procedure 2. Research purpose 
Specify purpose, discomfort likely to be felt and side effects, if any: Nil 
Whether blood sample collected will be stored after study period: Yes / No, it will be destroyed 
Whether blood sample collected will be sold: Yes / No 
Whether blood sample collected will be shared with persons from another institution: Yes / No 
Medication given, if any, duration, side effects, purpose, benefits: Nil 
Whether medication given is part of routine procedure: Yes / No (If not, state reasons for giving this 
medication) 
Whether alternatives are available for medication given: Yes / No (If not, state reasons for giving this 
particular 
medication) 
Final interview (specify approximate duration):_________ mts. If photograph is taken, purpose: Nil 
Benefits from this study: Nil 
Risks involved by participating in this study: Nil 
How the results will be used: It will be used for research purpose. 
If you are uncomfortable in answering any of our questions during the course of the interview / biological 
sample collection, you have the right to withdraw from the interview / study at anytime. 
  
You have the freedom to withdraw from the study at any point of time. Kindly be assured that your refusal to 
participate or withdrawal at any stage, if you so decide, will not result in any form of compromise or 
discrimination in the services offered nor would it attract any penalty. You will continue to have access to the 
regular services offered to a patient. You will NOT be paid any remuneration for the time you spend with us 
for this interview / study. The information provided by you will be kept in strict confidence. Under no 
circumstances shall we reveal the identity of the respondent or their families to anyone. The information that 
we collect shall be used for approved research purposes only. You will be informed about any significant 
new findings - including adverse events, if any, – whether directly related to you or to other participants of 
this study, developed during the course of this research which may relate to your willingness to continue 
participation. 
Consent: The above information regarding the study, has been read by me/ read to me, and has been 
explained to me by the investigator/s. Having understood the same, I hereby give my consent to them to 
interview me. I am affixing my signature / left thumb impression to indicate my consent and willingness to 
participate in this study (i.e., willingly abide by the project requirements). 
 
Signature / Left thumb impression of the Study Volunteer / Legal Representative: 
 
Signature of the Interviewer with date: Witness: 
 
Contact number of PI: 0422 4345230 
 
Contact number of Ethics Committee Office: 0422 4345818 
 
 
 
 
 
 
 
 
 
 
  
 
